Cost-effectiveness of screening for anal precancers in HIV-positive men

Jonathan M C Lam, Jeffrey S Hoch, Jill Tinmouth, Marie Sano, Janet Raboud, Irving E. Salit

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective: To assess the cost-effectiveness of high-resolution anoscopy (HRA), anal cytology, and anal human papillomavirus (HPV) detection in screening for histologic high-grade anal intraepithelial neoplasia (AIN 2/3) in HIV-positive MSM. Design: Participants were 401 HIV-positive MSM who were screened for anal cancer in a tertiary care HIV clinic. Methods: A decision analytical model was used to determine the cost-effectiveness of three anal cancer screening strategies: the direct use of HRA; HRA only if anal cytology was abnormal; and HRA only if oncogenic HPV was present. The model included the use of different thresholds for abnormal cytology and also combined cytology and HPV testing. The outcome was the number of AIN 2/3 cases detected. Costs were estimated from institutional data and sensitivity/specificity of cytology and HPV tests were obtained from the screening study. Results: The costs ($ US) per procedure for HRA, cytology, and HPV testing were $193, $90, and $95, respectively. The direct use of HRA was the most cost-effective strategy. It detected 98 individuals with AIN 2/3 and had a cost-effectiveness of $809 per AIN 2/3 case detected. Using probabilistic sensitivity analysis, three other strategies had similar costs per case detected and might be as cost-effective as HRA. Conclusion: In HIV-infected MSM, the direct use of HRA is the most cost-effective strategy for detecting AIN 2/3. The higher cost per use for HRA was offset by the high sensitivity and low specificity of HPV and cytology testing.

Original languageEnglish (US)
Pages (from-to)635-642
Number of pages8
JournalAIDS
Volume25
Issue number5
DOIs
StatePublished - Mar 13 2011
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Cell Biology
HIV
Costs and Cost Analysis
Anus Neoplasms
Sensitivity and Specificity
Tertiary Healthcare
Early Detection of Cancer
Neoplasms

Keywords

  • anal cancer
  • anal dysplasia
  • cost-effectiveness analysis
  • high-resolution anoscopy
  • human papillomavirus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Lam, J. M. C., Hoch, J. S., Tinmouth, J., Sano, M., Raboud, J., & Salit, I. E. (2011). Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS, 25(5), 635-642. https://doi.org/10.1097/QAD.0b013e3283434594

Cost-effectiveness of screening for anal precancers in HIV-positive men. / Lam, Jonathan M C; Hoch, Jeffrey S; Tinmouth, Jill; Sano, Marie; Raboud, Janet; Salit, Irving E.

In: AIDS, Vol. 25, No. 5, 13.03.2011, p. 635-642.

Research output: Contribution to journalArticle

Lam, JMC, Hoch, JS, Tinmouth, J, Sano, M, Raboud, J & Salit, IE 2011, 'Cost-effectiveness of screening for anal precancers in HIV-positive men', AIDS, vol. 25, no. 5, pp. 635-642. https://doi.org/10.1097/QAD.0b013e3283434594
Lam, Jonathan M C ; Hoch, Jeffrey S ; Tinmouth, Jill ; Sano, Marie ; Raboud, Janet ; Salit, Irving E. / Cost-effectiveness of screening for anal precancers in HIV-positive men. In: AIDS. 2011 ; Vol. 25, No. 5. pp. 635-642.
@article{aae1c585bf3f48fe912cbc0a92ff1944,
title = "Cost-effectiveness of screening for anal precancers in HIV-positive men",
abstract = "Objective: To assess the cost-effectiveness of high-resolution anoscopy (HRA), anal cytology, and anal human papillomavirus (HPV) detection in screening for histologic high-grade anal intraepithelial neoplasia (AIN 2/3) in HIV-positive MSM. Design: Participants were 401 HIV-positive MSM who were screened for anal cancer in a tertiary care HIV clinic. Methods: A decision analytical model was used to determine the cost-effectiveness of three anal cancer screening strategies: the direct use of HRA; HRA only if anal cytology was abnormal; and HRA only if oncogenic HPV was present. The model included the use of different thresholds for abnormal cytology and also combined cytology and HPV testing. The outcome was the number of AIN 2/3 cases detected. Costs were estimated from institutional data and sensitivity/specificity of cytology and HPV tests were obtained from the screening study. Results: The costs ($ US) per procedure for HRA, cytology, and HPV testing were $193, $90, and $95, respectively. The direct use of HRA was the most cost-effective strategy. It detected 98 individuals with AIN 2/3 and had a cost-effectiveness of $809 per AIN 2/3 case detected. Using probabilistic sensitivity analysis, three other strategies had similar costs per case detected and might be as cost-effective as HRA. Conclusion: In HIV-infected MSM, the direct use of HRA is the most cost-effective strategy for detecting AIN 2/3. The higher cost per use for HRA was offset by the high sensitivity and low specificity of HPV and cytology testing.",
keywords = "anal cancer, anal dysplasia, cost-effectiveness analysis, high-resolution anoscopy, human papillomavirus",
author = "Lam, {Jonathan M C} and Hoch, {Jeffrey S} and Jill Tinmouth and Marie Sano and Janet Raboud and Salit, {Irving E.}",
year = "2011",
month = "3",
day = "13",
doi = "10.1097/QAD.0b013e3283434594",
language = "English (US)",
volume = "25",
pages = "635--642",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cost-effectiveness of screening for anal precancers in HIV-positive men

AU - Lam, Jonathan M C

AU - Hoch, Jeffrey S

AU - Tinmouth, Jill

AU - Sano, Marie

AU - Raboud, Janet

AU - Salit, Irving E.

PY - 2011/3/13

Y1 - 2011/3/13

N2 - Objective: To assess the cost-effectiveness of high-resolution anoscopy (HRA), anal cytology, and anal human papillomavirus (HPV) detection in screening for histologic high-grade anal intraepithelial neoplasia (AIN 2/3) in HIV-positive MSM. Design: Participants were 401 HIV-positive MSM who were screened for anal cancer in a tertiary care HIV clinic. Methods: A decision analytical model was used to determine the cost-effectiveness of three anal cancer screening strategies: the direct use of HRA; HRA only if anal cytology was abnormal; and HRA only if oncogenic HPV was present. The model included the use of different thresholds for abnormal cytology and also combined cytology and HPV testing. The outcome was the number of AIN 2/3 cases detected. Costs were estimated from institutional data and sensitivity/specificity of cytology and HPV tests were obtained from the screening study. Results: The costs ($ US) per procedure for HRA, cytology, and HPV testing were $193, $90, and $95, respectively. The direct use of HRA was the most cost-effective strategy. It detected 98 individuals with AIN 2/3 and had a cost-effectiveness of $809 per AIN 2/3 case detected. Using probabilistic sensitivity analysis, three other strategies had similar costs per case detected and might be as cost-effective as HRA. Conclusion: In HIV-infected MSM, the direct use of HRA is the most cost-effective strategy for detecting AIN 2/3. The higher cost per use for HRA was offset by the high sensitivity and low specificity of HPV and cytology testing.

AB - Objective: To assess the cost-effectiveness of high-resolution anoscopy (HRA), anal cytology, and anal human papillomavirus (HPV) detection in screening for histologic high-grade anal intraepithelial neoplasia (AIN 2/3) in HIV-positive MSM. Design: Participants were 401 HIV-positive MSM who were screened for anal cancer in a tertiary care HIV clinic. Methods: A decision analytical model was used to determine the cost-effectiveness of three anal cancer screening strategies: the direct use of HRA; HRA only if anal cytology was abnormal; and HRA only if oncogenic HPV was present. The model included the use of different thresholds for abnormal cytology and also combined cytology and HPV testing. The outcome was the number of AIN 2/3 cases detected. Costs were estimated from institutional data and sensitivity/specificity of cytology and HPV tests were obtained from the screening study. Results: The costs ($ US) per procedure for HRA, cytology, and HPV testing were $193, $90, and $95, respectively. The direct use of HRA was the most cost-effective strategy. It detected 98 individuals with AIN 2/3 and had a cost-effectiveness of $809 per AIN 2/3 case detected. Using probabilistic sensitivity analysis, three other strategies had similar costs per case detected and might be as cost-effective as HRA. Conclusion: In HIV-infected MSM, the direct use of HRA is the most cost-effective strategy for detecting AIN 2/3. The higher cost per use for HRA was offset by the high sensitivity and low specificity of HPV and cytology testing.

KW - anal cancer

KW - anal dysplasia

KW - cost-effectiveness analysis

KW - high-resolution anoscopy

KW - human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=79952451155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952451155&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3283434594

DO - 10.1097/QAD.0b013e3283434594

M3 - Article

C2 - 21139488

AN - SCOPUS:79952451155

VL - 25

SP - 635

EP - 642

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -